Proactive Outreach to Focus on Increasing Awareness and Enhancing Shareholder Value

Novus Acquisition and Development Corp. (NDEV), the nation’s first healthcare insurance plan in the medical cannabis field and property and casualty sector, today announced that it has retained Hayden IR, a fifteen-year old, highly-recognized national investor relations firm. The focus of the engagement is to raise Novus’ visibility and strengthen its relationships with the investment community, increase awareness and enhance shareholder value.

Novus generates and services its members through their automated web portal at:https://www.getnovusnow.com. Over the past year, Novus insurance programs have diversified from a single oriented line of business, medical cannabis plans, to multiple liability and specialty lines of business and revenue streams. No one knows Novus’ brand in the cannabis space better than their own team, which is why they have taken control of their digital marketing approach from third party vendors to in-house marketing strategies resulting to cost-effectively convert and acquire customers.

“Over the past year, our Novus team has successfully taken a vision, implemented a business plan and created an infrastructure in the rapidly moving legalized cannabis industry. Our company is entering a very exciting phase as legalized medical cannabis continues to expand state-by-state and now encompasses 24 states. We are excited by our progress to-date as we look to take advantage of this emerging trend,” said Frank Labrozzi, Novus’ Chairman and Chief Executive Officer. “We believe it is an appropriate time to retain a national investor relations firm to help us target and expand our investor audience and ensure we are communicating effectively with Wall Street. We look forward to working with the team of professionals at Hayden IR to execute this important goal.”

Hayden IR is a premier investor relations consulting firm, connecting undervalued emerging growth companies with institutions, hedge funds, independent portfolio managers, buy-side and sell-side analysts, retail brokerage firms and accredited individual investors. Hayden’s team of IR professionals draw from “Wall Street,” finance, agency and media backgrounds and continuously strive to maximize the ongoing corporate visibility and market capitalization of clients though a comprehensive, multi-tier proactive program. Hayden IR always puts its clients in front of investors who can take action immediately, not when the client is larger or further along the corporate lifecycle. Over time, Hayden IR helps its clients navigate up the Wall Street food chain, broadening their audience. Hayden IR also consistently adds to its database, from online tools and conferences, as it builds relationships, one at a time, so there is a history and an understanding of each contact; it’s not just a name in the database. The Hayden IR team brings dozens of years of collective experience and brings a range of expertise to the benefit of its clients.

Stephen Hart, Head of Corporate Advisory at Hayden IR, added, “We are very excited to be working with Novus, a company with a unique and much-needed product offering in an underserved emerging growth market. Its business model and plans for expansion into additional insurance lines of business and revenue streams, make Novus well positioned to take advantage of the expected growth of regulated cannabis over the next few years. The team at Hayden IR looks forward to articulating this opportunity to the professional investment community.”

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary Novus Medical Group, Inc. and WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.

Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.